Amgen Inc. (AMGN) Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults with generalized myasthenia gravis, a rare autoimmune disorder. The study met its primary goal.
The primary endpoint of the study was change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score, which assesses how myasthenia gravis symptoms affect daily activities. The study included patients who are acetylcholine receptor autoantibody-positive (AChR+) and those who are muscle-specific kinase autoantibody-positive (MuSK+). The antibodies acetylcholine receptor and muscle-specific kinase can be found in the blood of people with myasthenia gravis.
Results from the study showed that Uplizna demonstrated clinically meaningful and statistically significant efficacy in both AChR+ and MuSK+ patients.
These results will be presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18 in Savannah, Georgia.
Uplizna is already approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease of the central nervous system.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.